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A B S T R A C T 
Background: There are no data of efficacy comparison between primary systemic 
therapy in stage 3B and 4 breast cancer patients in Indonesia. This study compared 
long term outcomes of breast cancer patients treated with neoadjuvant hormonal 
therapy (NAHT) and those treated with neoadjuvant chemotherapy (NACT) 
Methods: This was a cohort study conducted from 2011 to 2017. A total of 122 
patients with stage 3B and 4 breast cancer received NAHT (n = 62) or NACT (n = 60) 
within a 6 cycles for NACT and 6 months for NAHT were included. Patients were 
excluded if they had a mastectomy before treatment, were pregnant, had been given 
hormonal therapy or chemotherapy before, had a contra-indication of chemotherapy, 
had a contra-indication of salpingo-oophorectomy bilateral for premenopausal 
patients, and declined to enter this study. The primary outcome of this study was 
overall survival. The outcomes were analysed using Kaplan-Meier for survival analysis 
and cox proportional hazard regression to estimate the hazard ratio. 
 
Results: There was a statistically significant difference in overall survival (p = 0.038). 
Median overall survival for NAHT patients was 1265 days and for NACT patients was 
654 days. The hazard ratio showed NACT patients had a higher risk than NAHT patients 
(1.7 95% CI 1.03 – 2.9). Pathological complete response rate was higher in the NACT 
group than in the NAHT group (3.3% vs. 0%). 
 
Conclusions: Neoadjuvant hormonal therapy was superior to neoadjuvant 
chemotherapy in term of overall survival. 
 
 
 
INTRODUCTION 
 
Systemic therapy of breast cancer has been 
conducted for the last hundred years since Beatson in 
1896 first demonstrated that ovarium ablation changes 
hormonal balancing in woman with breast cancer (1). 
Today, the choice of chemotherapy or hormonal 
therapy for breast cancer patients depends on 
technological advancement such as 
immunohistochemistry and biomolecular assay. For 
early breast cancer, several genomic tests have been 
developed to more accurately predict clinical outcomes 
of chemotherapy and hormonal therapy dependent on 
individual biological characteristics (2-4). One study with 
gene expression profiling showed that approximately 
30% of breast cancer patients who received 
chemotherapy did not actually require that treatment 
(2,4,5). However, it is different for advanced breast 
cancer of which the determination for using systemic 
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therapy depends on only hormonal receptor status 
examination (6). 
As a care treatment, neoadjuvant systemic therapy 
is a standard treatment for inoperable patients (7). It 
offers clinical advantages to reduce tumor size, may 
increase the proportion of eligible patients for surgical 
resection or breast-conserving surgery, determine the 
responses to primary systemic therapy (PST) in vivo, and 
to determine the changes of the cells after drug 
administration and lead to subsequent treatment 
decisions (7-10). The administration of neoadjuvant 
systemic therapy varies from 4 cycles until 6 cycles.    
The Indonesian guideline of systemic therapy for 
breast cancer patients still follows the guideline from 
Caucasian population. Thus, it may not be suitable for 
Indonesian population since there are notable 
differences between the Asian and Caucasian race 
based on clinical parameters, morphology and genetic 
factors (11). This study compared the efficacy between 
two types of primary systemic treatment for advanced 
breast cancer: neoadjuvant hormonal therapy (NAHT) 
and those treated with neoadjuvant chemotherapy 
(NACT). 
    
METHODS 
Participants 
This was a prospective cohort study conducted from 
2011 to 2017 at Dharmais National Cancer Center 
Hospital, Indonesia. Patients with stage 3B and 4 breast 
cancer received NAHT for 6 months or NACT within 6 
cycles were included. Criteria for 3B and 4 were based 
on American Joint Committee on Cancer 7th edition 
guideline (12). ER and PR status were determined by 
immunohistochemistry test (13). Her2 status was 
determined by immunohistochemistry resulting in 4 
categories: Her2-negative, positive grade 1, positive 
grade 3 and positive grade 2 which was reconfirmed by 
performing FISH. Classification of histopathologic grade 
was based on the Nottingham Grading System. Patients 
were excluded if they had a mastectomy before 
treatment, were pregnant, declined to enter this study, 
had been given hormonal therapy or chemotherapy 
before, had a contra-indication of chemotherapy, and 
had contra-indication of salpingo-oophorectomy 
bilateral (SOB) for premenopausal patients. Patient 
follow up was done continuously to obtain data of 
death, censored patients, and patients with new 
symptoms.  
Intervention 
There were 122 patients included in this study (62 of 
NAHT patients and 60 of NACT patients). The study was 
open-label and non-randomized. Patients were assigned 
to one of two treatments (NAHT or NACT) by choosing 
the treatment based on their preferences after the 
advantages and disadvantages between NAHT and NACT 
had been explained to them. The NAHT group received 
Aromatase Inhibitor (AI) or Tamoxifen for 
postmenopausal patients and for premenopausal 
patients, they received Tamoxifen only or SOB and 
AI/Tamoxifen, or if patients rejected SOB they would 
receive GNRH-analogue and AI/Tamoxifen which was 
given for 6 months. AI consisted of Letrozole, 
Anastrozole, and Exemenestane. The NACT group 
received FAC (5-Fluorouracil, Adriamycin, and 
Cyclophosphamide) which was given for 6 cycles. After 
treatment, the patients were then able to receive a 
mastectomy when a surgically technique was possible. If 
not possible the patient was only able to get a second 
biopsy. The patient criteria for receiving a mastectomy 
was when the tumor was not sticking to the chest wall, 
not beyond the bounds of the breast and a Karnofski 
score higher than 90%.  All patients agreed to enter this 
study by signing the written inform consent. The flow 
diagram of the participants is shown in Figure 1. 
This study was approved by Ethical Committee at 
Dharmais Hospital-National Cancer Center, Indonesia 
(Number of Ethic Approval: 049/PEP/08/2011) and 
registered in ClinicalTrials.gov (number NCT02995772). 
Outcomes and Statistical Methods 
The primary end point of this study was overall 
survival and the secondary end point was progression 
free survival (PFS). Overall survival was defined as the 
length of time from the date of pathological diagnosis 
until death from any cause. PFS was defined as the 
length of time from after treatment until tumor 
progression or death from any cause. Pathological 
complete response (pCR) was defined as the absence of 
residual invasive and in situ breast cancer following 
completion of neoadjuvant systemic therapy. In this 
study, pCR was defined by pathology anatomy result. 
Statistical analyses were done with SPSS IBM version 
21.0 and data management was done with Microsoft 
Excel 2010. The study used Kaplan-Meier survival 
analysis to produce overall survival and progression free 
survival. Overall survival was an output of NAHT and 
NACT comparison which was analyzed from survival 
time and events (deaths). Progressive free survival was 
an output of time-lapse of tumor progression after 
neoadjuvant systemic therapy. Hazard ratio (HR) was 
estimated using Cox proportional hazard regression. 
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Figure 1. Research workflow 
 
RESULTS 
 
Table 1. Patients’ characteristics 
Characteristics
a
 NAHT (n = 62) NACT (n = 60) P-value
b
 
Age (year), mean (SD) 45.7 (9.3) 49.8 (10.5) 0.023
c
 
Range 22 – 68  27 – 75 
Stage   0.011
d
 
     Stage 3B 25 (39.7) 38 (60.3) 
     Stage 4 37 (62.7) 22 (37,3) 
Grade   0.03
d
 
     Low Grade (I and II) 39 (60) 26 (40) 
     High Grade (III) 23 (40.4) 34 (59.6) 
Histological Type   0.54
d
 
     Ductal 56 (50) 56 (50) 
     Lobular 6 (60) 4 (40) 
Hormonal Receptor   < 0.0001
d
 
     Positive 59 (64.1) 33 (35.9) 
     Negative 3 (10) 27 (90) 
Her2 Status   0.25
d
 
     Positive
e
 13 (41.9) 18 (58.1) 
     Negative 49 (53.8) 42 (46.2) 
PCR Rate   0.14
d
 
     N 0 2 
     % 0 3.3 
Mastectomy   0.44
d
 
     Yes 43 (48.3) 46 (51.7) 
     No 18 (56.3) 14 (43.8) 
Metastase in Stage IV (n = 57)   0.2
d
 
     Visceral (lung and liver) 16 (55.2) 13 (44.8) 
     Non-visceral (bone) 20 (71.4) 8 (28.6) 
Death/Alive   0.47
d
 
     Death 29 (52.5) 32 (47.5) 
     Alive 33 (54.1) 28 (45.9) 
NAHT= neoadjuvant hormonal therapy; NACT= neoadjuvant chemotherapy; PCR rate= pathologic complete response rate; 
SD= standard deviation 
a
 Values are number percentage 
b
 Significant value (p-value) set at 0,05 ad two tailed; c Independent sample t-test; d Pearson’s Chi Square 
e 
Hormonal receptor status positive was from estrogen receptor status positive and/or progesterone receptor status 
positive.
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This research found the mean of patients’ age of 
45.7 years old + 9.3 years (for NAHT group) and 49.8 
years old + 10.5 years (for NACT group). The youngest 
patient for NAHT and NACT group were 22 and 27 years 
old. The oldest patient for NAHT and NACT group were 
68 and 75 years old. Pathological complete response 
(pCR) rate was higher in the NACT group than in the 
NAHT group (3.3% vs. 0%). The patients characteristics 
in this study are shown in Table 1. 
The total number of patients was 122 (62 of NAHT 
patients and 60 of NACT patients). There were statistical 
differences in OS (p = 0.038). Median of overall survival 
was 1265 days for NAHT and 654 days for NACT. The 
hazard ratios of overall survival by Kaplan-Meier curves 
(Figure 2) showed that NACT patients had higher risk of 
death than NAHT patients (1.7 95% CI 1.03–2.9). But, 
there weren’t statistical difference in PFS (p = 0.65) 
between NAHT and NACT.  
There were statistical differences of overall survival 
by mastectomy status and hormonal receptor status. 
Median of overall survival was 1174 days in patients 
assigned to mastectomy and 587 days in non-
mastectomy. The hazard ratios of overall survival by 
Kaplan-Meier curves (Figure 3) showed that patients 
that were not assigned to mastectomy had higher risk of 
death than patients assigned to mastectomy, and 
patients who had negative hormonal receptor had 
higher risk of death than patients who had positive 
hormonal receptor. Median of overall survival was 500 
days for patients who had negative hormonal receptor 
and 1265 days for patients who had positive hormonal 
receptor. 
 
 
Figure 2. Kaplan-Meier curves for survival by treatment arm (A) overall survival; (B) Progression-free survival 
 
 
Figure 3. Kaplan-Meier curves for overall survival by (A) mastectomy status; (B) hormonal receptor status 
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Figure 4. Forest plot of (A) overall survival, and (B) progression free survival in subgroup analysis 
 
 
DISCUSSION 
Findings from our study, there were statistically 
significant differences between NACT and NAHT in 
terms of age, stage, grade and hormonal receptor 
(Table 1). The age of patients that received NAHT is less 
than NACT. In older patients, there was a statistically 
significant difference and the Hazard Ratio was 1,8 
times higher risk for death for NACT compared to NAHT 
(Figure 4), which is different with Marcus’s study in 
2013, where NACT is likely to reduce the risk of future 
outcomes in younger patients (14). Traditionally, NAHT 
is given predominantly to fragile postmenopausal 
patients with poor condition and NACT tends to be 
given to premenopausal patients to achieve a rapid 
response prior to surgery if technically possible (14-16).  
Numerous study of neoadjuvant systemic therapy 
had used pCR as their endpoint. However, a common 
definition of pCR had not been defined until recently 
(17). Our results showed that NACT has higher pCR rate 
than NAHT (Table 1). The NSABP B-18 and B-27 study 
showed a pCR of NACT patients of 13%. This rate was 
higher than our result because the study was conducted 
in early stage breast cancer patients (18). We also found 
patients with HR-positive, which contrast to some 
studies which demonstrated HR-negative tumor had 
higher pCR rate than HR-positive tumor (19,20). 
Nevertheless, there were studies that concluded pCR 
rate could not predict survival rate (21,22). 
To date, there are still few studies comparing the 
efficacy of NACT and NAHT in breast cancer patients. 
Although there are such studies, generally the number 
of patients is small, overall survival is not frequently 
obtained and mostly the studies were only done on the 
positive hormone receptor group. In our study, we 
obtained statistically significant values in overall survival 
from comparing NAHT and NACT. 
In our case, using various hormonal drugs, the 
results demonstrated that median survival was longer 
than NACT patients, median OS and PFS were 1265 days 
and 202 days for NAHT and 654 days and 187 days for 
NACT patients, with statistically significant differences 
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(Figure 2). It is similar with other studies that showed 
patients who received NAHT alone had a longer median 
survival than patients who received NACT alone 
(14,21,23,24). 
In this study, 75.4% patients were hormone receptor 
(HR) positive. HR is a good predictor of outcomes with 
neoadjuvant hormonal therapy. Earlier, HR was 
classified with a cut-off point of 10% to be able to 
response to hormonal therapy. Until now, there is no 
study comparing NACT and NAHT with an HR cut off 
point of 1% for advanced breast cancer and we 
attempted to use a cut-off point of 1% in this study (13). 
Our result for HR positive in this population was similar 
with Cochrane meta-analysis study that also found no 
difference in overall survival between patients receiving 
hormonal therapy and chemotherapy (25), but NAHT 
patients tend to have longer median overall survival 
than NACT patients. This demonstrates that for 
advanced breast cancer patients, a 1% cut-off for HR-
positive patients can still be used as a guide to received 
NAHT when the aim of treatment is palliation. In this 
study, we did not use trastuzumab as one of the 
treatments for patients with Her2 positive advanced 
breast cancer, because currently trastuzumab is not 
covered for this indication by the national healthcare 
insurance. 
To our knowledge, there is still no study comparing 
chemotherapy and hormonal therapy in HR-negative 
breast cancer patients. Standard treatment for HR-
negative advanced breast cancer patients is 
chemotherapy (6). In this study, there were only 3 
patients with HR-negative status who received NAHT 
because they rejected chemotherapy. Median overall 
survival time of NAHT HR-negative patients was longer 
than for NACT HR-negative (658 days and 423 days) but 
not statistically significant and NACT patients have 
higher risk of death than NAHT patients although 
patient number was small (HR 4.1 95% CI 0.5-30.7). 
In this study, after receiving 6 cycles of 
chemotherapy or 6 months of hormonal therapy, 
patients would undergo a mastectomy if technically 
possible. The number of mastectomy patients was 
almost three times of non-mastectomy patients. 
Patients who underwent mastectomy after treatment 
had a statistically significant longer median survival than 
non-mastectomy patients (Figure 3). These results were 
similar to research conducted by Robertson et al., 
where the life span of patients undergoing mastectomy 
is better than with tamoxifen alone. Over a 24 month 
period only 47% of patients survived when tamoxifen 
alone was used, versus almost 70% when mastectomy 
was performed (26). However, there may have been 
selection bias since only patients in good condition 
underwent mastectomy. According to systemic therapy, 
patients showed better OS and PFS with NAHT than 
NACT for all of the above characteristics (Figure 4), 
although some of the results were not statistically 
meaningful. This suggests that for patients with 
advanced cancer, chemotherapy has no benefit. It was 
not similar with Badwe et al. (27), because this study did 
not only study about advanced breast cancer (4 stage) 
but also included 3B stage. 
The strength of this study is the estimation survival 
between two arms regardless of HR status. Another 
strength is related to treatment responses, because 
there were patients who had HR-negative status but 
received hormonal therapy. The limitations were the 
small sample size and the lack of statistical significance 
in some results. Data distribution was not equal, since 
this study was not randomized and hence the 
researcher was less able to control disturbing factors. 
Another limitation is that we cannot use randomized 
clinical trial because there was an ethical problem. 
 
CONCLUSIONS 
 
The oncogenesis process in patients with advanced 
cancer has been completed. Therefore, the treatment 
should be palliative and should not worsen the quality 
of life of the patients. In summary, this study has shown 
that NAHT as initial treatment for stage 3B and 4 breast 
cancer offers longer OS than NACT regardless of HR 
status. The efficacy comparison of these two treatment 
options warrants further investigation with larger 
sample size and further exploration of the molecular 
background. 
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